Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new two-step method promises to revolutionize targeted cancer drug development by ...

Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...

The very first antibody-drug conjugates (ADCs) to enter clinical evaluation sought to improve the therapeutic index of approved anti-cancer drugs, such as doxorubicin and vinblastine, by linking them ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

Poster sessions to highlight encouraging preclinical data for NEOK001 (ABL206), a first-in-class bispecific ADC targeting B7-H3 and ROR1-expressing solid tumors, and NEOK002 (ABL209), a bispecific ADC ...

Cancer antigens targeted by drug conjugates are restricted to the few membrane receptors (such as HER2 and TROP2) that ...

Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

A two-antibody click-chemistry strategy improves targeted chemotherapy delivery to resistant HER2- and EGFR-positive tumors, boosting tumor control in mice.

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target ...